Ascendis Pharma A/S announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer, PROC, treated with TransCon IL-2 beta/gamma in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 beta/gamma. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024. Of the 18 patients included in the initial data, 14 were efficacy evaluable patients who had 1 or more post-baseline tumor assessment, plus an additional 4 who discontinued treatment before the first post-baseline tumor assessment due to disease progression or death. Anti-tumor clinical responses were observed in 29% of the efficacy evaluable patients including patients whose disease had previously progressed on Elahere, suggesting clinical activity in heavily pre-treated patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Secures FDA Orphan Drug Exclusivity
- Ascendis Pharma’s yorvipath granted orphan drug exclusivity in U.S.
- Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
- Ascendis Pharma Expands Capital and Issues Warrants
- Citi opens ‘positive catalyst watch’ on Ascendis into data